<DOC>
	<DOCNO>NCT00080678</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . Imatinib mesylate may stop growth tumor cell block enzymes necessary growth . Combining docetaxel imatinib mesylate may effective treatment androgen-independent prostate cancer bone metastasis . PURPOSE : This randomized phase II trial study docetaxel imatinib mesylate see well work compare docetaxel alone treat patient androgen-independent prostate cancer bone metastasis .</brief_summary>
	<brief_title>Docetaxel With Without Imatinib Mesylate Treating Patients With Androgen-Independent Prostate Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time progression patient androgen-independent prostate cancer bone metastasis treat docetaxel v without imatinib mesylate . Secondary - Compare response rate patient treat regimen . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord hemoglobin ( &lt; 11g/dL v ≥ 11 g/dL ) , alkaline phosphatase ( normal v elevate ) , number prior regimen ( 0 vs 1 2 ) , ECOG performance score ( 0 1 v 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV day 1 , 8 , 15 , 22 oral imatinib mesylate daily day 1-43 . - Arm II : Patients receive docetaxel arm I oral placebo daily day 1-43 . In arm , course repeat every 43 day absence disease progression unacceptable toxicity . Patients progress arm II may cross arm I . PROJECTED ACCRUAL : A total 152 patient ( 76 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma prostate Osseous metastasis confirm radiography Lytic bone lesion consider biopsy clinical suspicion histologic conversion small cell carcinoma Failed prior hormonal therapy Progressive disease , evidence one following : 2 consecutive rise prostatespecific antigen ( PSA ) least 1 ng/mL 4 week Increase 25 % product bidimensional disease 30 % maximum diameter Increase number osseous metastasis bone scan Worsening symptom attributable disease progression ( e.g. , worsen bony pain ) PSA ≥ 1 ng/mL Castrate serum testosterone ≤ 50 ng/dL Concurrent luteinizinghormone releasinghormone analog require medically castrated patient No small cell sarcomatoid prostate cancer No uncontrolled CNS metastases PATIENT CHARACTERISTICS : Age Any age Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy At least 3 month Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) ≤ 2 time upper limit normal No chronic liver disease Renal Creatinine clearance ≥ 40 mL/min Cardiovascular No New York Heart Association class III IV congestive heart failure No unstable angina No myocardial infarction within past 6 month No evidence myocardial ischemia electrocardiogram No uncontrolled severe hypertension Pulmonary No oxygendependent lung disease Other HIV negative No concurrent severe infection No contraindication corticosteroids No uncontrolled diabetes mellitus No grade 2 great peripheral neuropathy No malignancy within past 2 year except nonmelanoma skin cancer No overt psychosis , mental disability , incompetency would preclude give informed consent No history noncompliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior taxanes No 2 prior chemotherapy regimen At least 30 day since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy See Disease Characteristics At least 4 week since prior flutamide nilutamide* At least 6 week since prior bicalutamide* NOTE : *Unless evidence interim disease progression Radiotherapy At least 90 day since prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium recover At least 30 day since prior radiotherapy recover Surgery Fully recover prior surgery Other No concurrent ketoconazole No concurrent warfarin</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>